Within the framework of International R&D Nuclis call organized by ACCIÓ, Cytes Biotechnologies has been chosen as a success case for having won the grant that will promote its expansion and international growth.

For this reason, Jordi Xapelli, CEO of Cytes Biotechnologies, SL participated in a talk that took place last Friday, July 17th, where he explained the progress of the project in which the company is involved within this framework.

The aim of this talk was to promote the realization of R+D activities carried out in Catalonia and to facilitate international technological cooperation with foreign entities.

Fuente: CYTES BIOTECHNOLOGIES, SL.

https://www.cytesbiotechnologies.com/acci%C3%B3
Subscribirse al Directorio
Escribir un Artículo

Últimas Noticias

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

La exposición al frío y al calor duran...

El equipo de investigadores observó cambios en el...

Uso de RNA móviles para mejorar la asim...

El gen AtCDF3 promueve una mayor producción de az...

Destacadas

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

En nuestro post hablamos sobre este interesante tipo de célula del si...

Macro Biologics y Curapath fortalecen su...

by Curapath

Curapath se complace en reconocer el importante avance logrado por Mac...

Diapositiva de Fotos